Sugi Predict

Sugi Predict / Compounds / SCHEMBL4744830

SCHEMBL4744830

SCHEMBL4744830

NC(=O)C1(c2ccccc2F)CC1

nearest known ligand 0.57

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ HDAC4 P56524 4/20 0.57
▸ OPRL1 P41146 2/20 0.56
▸ ELOVL1 Q9BW60 8/20 0.45
▸ ALDH1A1 P00352 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ MAPT P10636 2/20 0.39
▸ THRB P10828 1/20 0.39
▸ HDAC3 O15379 1/20 0.38
▸ HDAC1 Q13547 1/20 0.38
▸ HDAC2 Q92769 1/20 0.38
▸ HDAC6 Q9UBN7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL43075 0.94 HDAC4 (0.65) HDAC4OPRL1ELOVL1ALDH1A1LMNA
SCHEMBL10002458 0.94 HDAC4 (0.60) HDAC4OPRL1ELOVL1ALDH1A1LMNA
SCHEMBL3842808 0.93 HDAC4 (0.63) HDAC4OPRL1ALDH1A1LMNAMAPT
Hydrochloric Acid SCHEMBL8642813 0.87 OPRL1 (0.49) HDAC4OPRL1ELOVL1ALDH1A1LMNA
SCHEMBL1259168 0.82 HDAC4 (0.59) HDAC4OPRL1ELOVL1MAPTTHRB
SCHEMBL31125559 0.82 HDAC4 (0.59) HDAC4OPRL1ELOVL1
SCHEMBL301133 0.82 HDAC4 (0.59) HDAC4OPRL1ELOVL1
SCHEMBL20241935 0.81 HDAC4 (0.57) HDAC4OPRL1ELOVL1ALDH1A1MAPT
SCHEMBL18742673 0.80 HDAC4 (0.62) HDAC4OPRL1ELOVL1LMNAHDAC3
SCHEMBL3860372 0.80 HDAC4 (0.42) HDAC4OPRL1ELOVL1LMNAHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109563085-B Piperidine CXCR7 receptor modulators 爱杜西亚药品有限公司 2022-08-09 — — CN claimed
EP-3490986-B1 PIPERIDINE CXCR7 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2021-11-24 — — EP claimed
US-10752620-B2 Piperdine CXCR7 receptor modulators IDORSIA PHARMACEUTICALS LTD. (CH) 2020-08-25 — — US claimed
US-20190169180-A1 PIPERDINE CXCR7 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD. (CH) 2019-06-06 — — US claimed
EP-3490986-A1 PIPERIDINE CXCR7 RECEPTOR MODULATORS Idorsia Pharmaceuticals Ltd (CH) 2019-06-05 — — EP claimed
CN-109563085-A piperidine CXCR7 receptor modulators 爱杜西亚药品有限公司 2019-04-02 — — CN claimed
WO-2018019929-A1 PIPERIDINE CXCR7 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2018-02-01 — — WO claimed
US-11746091-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2023-09-05 — — US disclosed
EP-3798217-B1 PIPERIDINE CXCR7 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2023-02-22 — — EP disclosed
US-20230033510-A1 Compounds and Methods for Treatment of Visceral Pain ARENA PHARMACEUTICALS, INC. 2023-02-02 — — US disclosed
CN-109563085-B Piperidine CXCR7 receptor modulators 爱杜西亚药品有限公司 2022-08-09 — — CN disclosed
CN-110563717-B Piperidine CXCR7 receptor modulators 爱杜西亚药品有限公司 2022-08-09 — — CN disclosed
US-20220144829-A1 AMINO ACID COMPOUNDS AND METHODS OF USE PLIANT THERAPEUTICS, INC. 2022-05-12 — — US disclosed
WO-2018019929-A1 PIPERIDINE CXCR7 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2018-02-01 — — WO disclosed
CN-102596913-B Cannabinoid receptor modulators 艾尼纳制药公司 2016-11-09 — — CN disclosed
US-8778950-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2014-07-15 — — US disclosed
US-20130165412-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2013-06-27 — — US disclosed
US-20120214766-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2012-08-23 — — US disclosed
EP-2470508-A1 CANNABINOID RECEPTOR MODULATORS Arena Pharmaceuticals, Inc. (US) 2012-07-04 — — EP disclosed
WO-2008099165-A1 PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES ASTRAZENECA AB (SE) 2008-08-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214766-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 HDAC4 2986/4885OPRL1 4/4885ELOVL1 1400/4885
US-20220144829-A1 AMINO ACID COMPOUNDS AND METHODS OF USE ITGB6, ITGA1, ITGAL HDAC4 2407/4885OPRL1 999/4885ELOVL1 468/4885
US-20190169180-A1 PIPERDINE CXCR7 RECEPTOR MODULATORS CXCR1, CXCR5, ACKR3 HDAC4 2022/4885OPRL1 50/4885ELOVL1 3765/4885
US-11746091-B2 Cannabinoid receptor modulators CNR1, CNR2, TRPV1 HDAC4 2986/4885OPRL1 4/4885ELOVL1 1400/4885
US-20230033510-A1 Compounds and Methods for Treatment of Visceral Pain VIP, FABP2, FABP6 HDAC4 1120/4885OPRL1 12/4885ELOVL1 868/4885
US-20130165412-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 HDAC4 2986/4885OPRL1 4/4885ELOVL1 1400/4885
US-10752620-B2 Piperdine CXCR7 receptor modulators CXCR1, CXCR5, ACKR3 HDAC4 2022/4885OPRL1 50/4885ELOVL1 3765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.